ZetaChain bug warning ignored before $334K exploit
ZetaChain has revealed that a vulnerability exploited in its recent $334,000 attack had previously been reported through its bug bounty programme but was dismissed as intended behaviour.
ZetaChain has revealed that a vulnerability exploited in its recent $334,000 attack had previously been reported through its bug bounty programme but was dismissed as intended behaviour.
ZetaChain has revealed that a vulnerability exploited in its recent $334,000 attack had previously been reported through its bug bounty programme but was dismissed as intended behaviour.
Jerome Powell said he will remain on the Federal Reserve Board of Governors after his term as chair ends on May 15, marking the first such move since 1948.
Jerome Powell said he will remain on the Federal Reserve Board of Governors after his term as chair ends on May 15, marking the first such move since 1948.
Woolworths Group has reported a 4.5% increase in third-quarter sales to $18.1 billion, but the retail giant simultaneously warned of a potential hit to its profit margins.
Woolworths Group has reported a 4.5% increase in third-quarter sales to $18.1 billion, but the retail giant simultaneously warned of a potential hit to its profit margins.
Canada’s Department of Finance has proposed a nationwide ban on Bitcoin and crypto ATMs as part of efforts to curb rising fraud targeting vulnerable individuals.
Canada’s Department of Finance has proposed a nationwide ban on Bitcoin and crypto ATMs as part of efforts to curb rising fraud targeting vulnerable individuals.
Microsoft (NASDAQ:MSFT) reported financial results for the quarter ended March 31, 2026, showcasing the compounding returns of its multi-year investment in generative artificial intelligence.
Microsoft (NASDAQ:MSFT) reported financial results for the quarter ended March 31, 2026, showcasing the compounding returns of its multi-year investment in generative artificial intelligence.
Costamare (NYSE:CMRE) today announced strong financial results for the first quarter of 2026, highlighted by a significant long-term expansion of its charter backlog and a signal of increased returns to shareholders.
Costamare (NYSE:CMRE) today announced strong financial results for the first quarter of 2026, highlighted by a significant long-term expansion of its charter backlog and a signal of increased returns to shareholders.
Wingstop (NASDAQ:WING) reported financial results for the first quarter of fiscal 2026 on Wednesday, April 29, 2026, highlighting a period of aggressive global expansion and disciplined capital allocation.
Wingstop (NASDAQ:WING) reported financial results for the first quarter of fiscal 2026 on Wednesday, April 29, 2026, highlighting a period of aggressive global expansion and disciplined capital allocation.
Regeneron Pharmaceuticals (NASDAQ:REGN) reported strong financial results for the first quarter of 2026 on Wednesday, April 29, 2026, highlighted by high-double-digit revenue growth and significant regulatory milestones.
Regeneron Pharmaceuticals (NASDAQ:REGN) reported strong financial results for the first quarter of 2026 on Wednesday, April 29, 2026, highlighted by high-double-digit revenue growth and significant regulatory milestones.
Lemonade (NYSE:LMND) delivered a stronger-than-anticipated start to the 2026 fiscal year, reporting first-quarter financial results that exceeded analyst projections on both the top and bottom lines.
Lemonade (NYSE:LMND) delivered a stronger-than-anticipated start to the 2026 fiscal year, reporting first-quarter financial results that exceeded analyst projections on both the top and bottom lines.
Shanghai Henlius Biotech and Organon (NYSE:OGN) announced on Wednesday, April 29, 2026, that the European Commission (EC) has granted marketing authorization for POHERDY (pertuzumab), making it the first and only approved biosimilar to the reference product PERJETA in Europe.
Shanghai Henlius Biotech and Organon (NYSE:OGN) announced on Wednesday, April 29, 2026, that the European Commission (EC) has granted marketing authorization for POHERDY (pertuzumab), making it the first and only approved biosimilar to the reference product PERJETA in Europe.